PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy.

"data availability we utilized multiple geo datasets including gse120575"

"the code used in our analysis is available on github ( https://github com/levy0803/nr4a1 ).; the code used in our analysis is available on github ( https://github com/levy0803/nr4a1 )."

"Disclosures: L. Wang reported grants from Sanofi during the conduct of the study; in addition, L. Wang had a patent to Modulators of Nuclear Receptor Subfamily 4 Group A Member 1 (NR4A1) and Uses Thereof issued. D.R. Shaffer reported being an employee of Sanofi, a global healthcare and pharmaceutical company, where he receives a salary and stock awards for his work. K.S.M. Smalley reported grants from Revolution Medicines outside the submitted work. D. Zhou reported grants from Sanofi during the conduct of the study; in addition, D. Zhou had a patent to US Patent Application No: 18/023,696 pending. G. Zheng reported a patent to WO2022/072094 pending. W. Zhang reported grants from Sanofi during the conduct of the study; in addition, W. Zhang had a patent to US 2023/0330237 A1 issued. No other disclosures were reported."

"The work is mainly supported by the Department of Defense/Congressionally Directed Medical Research Programs grant BC200100 (partnering principal investigators [PIs]: W. Zhang and G. Zheng) and an iAward from Sanofi (PI: W. Zhang). The work is partially supported by National Institutes of Health grants CA269662 (W. Zhang), CA260239 (W. Zhang; D. Zhou; G. Zheng), and CA290792 (W. Zhang; G. Zheng; K.S.M. Smalley). W. Zhang was also supported by an endowment fund from the Dr. and Mrs. James Robert Spenser Family. Open Access funding provided by the University of Florida. Author contributions: Funding: W. Zhang and G. Zheng; Conception and design: W. Zhang, G. Zheng, L. Wang, and Y. Xiao; Development of methodology: L. Wang, Y. Xiao, Y. Luo, R.P. Master, J. Mo, M.-C. Kim, Y. Liu, E. Moser, and D. Lv; Acquisition of cancer specimens and data: L. Wang, Y. Xiao, Y. Luo, R.P. Master, J. Mo, M.-C. Kim, Y. Liu, U.M. Patel, and W. Zhang; Analysis and interpretation of data: L. Wang, Y. Xiao, X. Li, D.R. Shaffer, K.R. Guertin, G. Zheng, and W. Zhang; Writing, review, and/or revision of the manuscript: L. Wang and Y. Xiao for the first draft; W. Zhang, G. Zheng, K.S.M. Smalley, D. Zhou, and D. Lv for rewriting, revision, and editing; Supervision: W. Zhang and G. Zheng. Disclosures: L. Wang reported grants from Sanofi during the conduct of the study; in addition, L. Wang had a patent to Modulators of Nuclear Receptor Subfamily 4 Group A Member 1 (NR4A1) and Uses Thereof issued. D.R. Shaffer reported being an employee of Sanofi, a global healthcare and pharmaceutical company, where he receives a salary and stock awards for his work. K.S.M. Smalley reported grants from Revolution Medicines outside the submitted work. D. Zhou reported grants from Sanofi during the conduct of the study; in addition, D. Zhou had a patent to US Patent Application No: 18/023,696 pending. G. Zheng reported a patent to WO2022/072094 pending. W. Zhang reported grants from Sanofi during the conduct of the study; in addition, W. Zhang had a patent to US 2023/0330237 A1 issued. No other disclosures were reported."